glp 1 pancreatic cancer Can GLP-1 medications really lower your risk? 🧐 Because obesity is linked to 13 types of cancer, researchers are seeing positive trends connecting weight-loss drugs to cancer prevention. James L. Wells GLP-1 Drugs for Type 2

Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, Andreasen AH, Jensen CB, DeFronzo RA

In obesity, Novos Wegovy (semaglutide injection) was approved in 2021, however uptake has been hindered by access limitations, with no Medicare coverage and limited coverage among commercial plans

[DOI] [PubMed] [Google Scholar] 58.Pang J., Choi Y., Park T

Motor disturbances/hypoactivity Another concern with therapies targeting the mesolimbic system is that the behavioral outcomes obtained are not specific to ingestive behavior and mediated via a general increase or decrease in physical activity

GLP-1 and GIP receptor agonists in combination have been found to have additive therapeutic effects

NPY and PYY A part of the pancreatic polypeptide family, NPY is a 36-amino acid peptide